Brett A. Pletcher
Net Worth

Last updated:

What is Brett A. Pletcher net worth?

The estimated net worth of Mr. Brett A. Pletcher is at least $29,002,193 as of 10 Jun 2022. He owns shares worth $3,830,938 as insider, has earned $6,201,255 from insider trading and has received compensation worth at least $18,970,000 in Gilead Sciences, Inc..

What is the salary of Brett A. Pletcher?

Mr. Brett A. Pletcher salary is $2,710,000 per year as Executive Vice President of Corporation Affairs, Gen. Counsel & Corporation Sec. in Gilead Sciences, Inc..

How old is Brett A. Pletcher?

Mr. Brett A. Pletcher is 57 years old, born in 1968.

What stocks does Brett A. Pletcher currently own?

As insider, Mr. Brett A. Pletcher owns shares in one company:

Company Title Shares Price per share Total value
Gilead Sciences, Inc. (GILD) Executive Vice President of Corporation Affairs, Gen. Counsel & Corporation Sec. 32,576 $117.6 $3,830,938

What does Gilead Sciences, Inc. do?

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

GILD logo
GILD
Gilead Sciences, Inc.
$117.6

Brett A. Pletcher insider trading

Gilead Sciences, Inc.

Mr. Brett A. Pletcher has made 23 insider trades between 2018-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 15,000 units of GILD stock on 25 Nov 2019. As of 10 Jun 2022 he still owns at least 32,576 units of GILD stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Unit 782 N/A N/A
Option
Common Stock 782 N/A N/A
Option
Restricted Stock Unit 2,593 N/A N/A
Option
Restricted Stock Unit 3,130 N/A N/A
Sale
Common Stock 3,634 $58.24 $211,644
Option
Common Stock 3,130 N/A N/A
Option
Common Stock 2,593 N/A N/A
Sale
Common Stock 1,691 $63.89 $108,038
Option
Restricted Stock Unit 2,727 N/A N/A
Option
Common Stock 2,727 N/A N/A
Sale
Common Stock 14,061 $68.54 $963,685
Sale
Common Stock 1,486 N/A N/A
Option
Restricted Stock Unit 2,593 N/A N/A
Option
Common Stock 2,593 N/A N/A
Sale
Common Stock 1,975 N/A N/A
Option
Common Stock 2,728 N/A N/A
Option
Restricted Stock Unit 2,728 N/A N/A
Sale
Common Stock 9,711 N/A N/A
Sale
Common Stock 13,210 $79.23 $1,046,642
Option
Common Stock 13,210 $32.43 $428,374
Option
Non-qualified Stock Option (Right to Buy) 12,560 $40.56 $509,434
Sale
Common Stock 2,950 $24.3 $71,670
Option
Common Stock 2,950 $24.3 $71,670
Option
Non-qualified Stock Option (Right to Buy) 2,950 $24.3 $71,670
Sale
Common Stock 10,441 $71.04 $741,770
Option
Non-qualified Stock Option (Right to Buy) 2,950 $24.3 $71,670
Option
Common Stock 2,950 $24.3 $71,670
Sale
Common Stock 2,950 $24.3 $71,670
Sale
Common Stock 1,426 $70 $99,820
Option
Restricted Stock Unit 2,728 N/A N/A
Option
Non-qualified Stock Option (Right to Buy) 5,000 $40.56 $202,800
Option
Common Stock 7,728 $20.28 $156,724
Sale
Common Stock 5,000 $40.56 $202,800
Option
Common Stock 2,950 $24.3 $71,670
Option
Non-qualified Stock Option (Right to Buy) 2,950 $24.3 $71,670
Sale
Common Stock 2,950 $24.3 $71,670
Option
Non-qualified Stock Option (Right to Buy) 5,900 $24.3 $143,341
Sale
Common Stock 5,900 $24.3 $143,341
Option
Common Stock 5,900 $24.3 $143,341
Option
Non-qualified Stock Option (Right to Buy) 15,000 $40.56 $608,400
Sale
Common Stock 15,000 $40.56 $608,400
Option
Common Stock 15,000 $40.56 $608,400
Option
Common Stock 10,000 $24.3 $242,950
Sale
Common Stock 10,000 $24.3 $242,950
Option
Non-qualified Stock Option (Right to Buy) 10,000 $24.3 $242,950
Option
Non-qualified Stock Option (Right to Buy) 10,000 $24.3 $242,950
Option
Common Stock 10,000 $24.3 $242,950
Sale
Common Stock 10,000 $24.3 $242,950
Sale
Common Stock 2,095 $66.06 $138,404
Option
Non-qualified Stock Option (Right to Buy) 2,400 $16.89 $40,536
Sale
Common Stock 4,000 $64.53 $258,100
Option
Common Stock 2,400 $16.89 $40,536
Sale
Common Stock 5,677 $63.31 $359,411
Sale
Common Stock 608 $64.35 $39,124
Option
Restricted Stock Unit 1,070 N/A N/A
Option
Common Stock 1,070 N/A N/A
Sale
Common Stock 7,200 $24.91 $179,316
Option
Non-qualified Stock Option (Right to Buy) 7,200 $24.91 $179,316
Option
Common Stock 7,200 $24.91 $179,316
Sale
Common Stock 5,816 $68.75 $399,850
Option
Common Stock 1,070 N/A N/A
Option
Restricted Stock Unit 1,070 N/A N/A
Option
Common Stock 2,000 N/A N/A
Option
Restricted Stock Unit 2,000 N/A N/A

Gilead Sciences key executives

Gilead Sciences, Inc. executives and other stock owners filed with the SEC: